8-K filed Jul 31, 2026 at 07:51 ET
AbbVie reported Q2 2026 adjusted EPS of $3.65, a 1.2% beat vs. consensus of $3.61, on revenue of $16.99B (above $16.76B consensus, +10.2% YoY). The company announced a definitive agreement to acquire Apogee Therapeutics for ~$10.9B and slightly lowered its full-year adjusted EPS guidance to $13.87-$14.07 to reflect the deal's $0.14 dilutive impact, partially offset by $0.10 of operational overperformance. Strong growth in immunology (Skyrizi +24.4%, Rinvoq +24.5%) and neuroscience (+20.3%) continues to offset Humira erosion (-35.9%).